CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,345 enrolled
Drug / intervention
Aeonosedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03346005
NCT03346005N/ACompleted
CompareCT.gov

Detection of Colorectal Cancer in Patients With a Positive Fecal Immunochemical Test Using an Electronic Nose Device (AeoNoseTM)

Radboud University Medical Center·interventional·Posted Nov 17, 2017·Updated Mar 16, 2020

In Brief

A clinical study evaluating Aeonose for Colorectal Cancer and Polyps of Colon. Completed, enrolled 3,345 participants across 1 site.

Detailed Summary

The present study aims to investigate the diagnostic accuracy of exhaled breath analysis with the Aeonose (the eNose Company, Zutphen, the Netherlands) to distinguish the breath of patients suspected for CRC (based on a positive fecal immunochemical test), who are truly diagnosed with CRC, from patients suspected for CRC in whom this diagnosis is rejected after colonoscopy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Polyps of Colon
CountriesNetherlands
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 17, 2017
Enrollment StartNov 9, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.6 years ago

Interventions

Aeonosedevice

An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.